These exosome nano-bioconjugates can release the antibodies after the selective cleavage in the acid tumor microenvironment that block the interaction between SIRPα and CD47, and thereby improve phagocytosis of macrophages [189]. The gene discussed is CD47; the disease is neoplasm.